Royal Nursing Center, Llc | |
359 Jones Rd, Falmouth, Massachusetts 02540 | |
(774) 345-0220 | |
Name | Royal Nursing Center, Llc |
---|---|
Location | 359 Jones Rd, Falmouth, Massachusetts |
Certified By | Medicare and Medicaid |
No. of Certified Beds | 121 |
Occupancy Rate | 62.64% |
Medicare ID (CCN) | 225459 |
Legal Business Name | Royal Nursing Center Llc |
Ownership Type | For Profit - Corporation |
NPI Number | 1265442438 |
Organization Name | FALMOUTH HEALTHCARE, LLC |
Doing Business As | FALMOUTH CARE AND REHABILITATION CENTER |
Address | 359 Jones Rd, Falmouth, MA 02540 |
Phone Number | 508-457-9000 |
News Archive
Radiation therapy using high-energy particles, like x-rays or electron beams, is a common and critical component in successfully treating patients with brain tumors, but it is also associated with significant adverse effects, such as neuronal loss in adjacent healthy tissues.
Sylvester Comprehensive Cancer Center researchers are looking at ways to combine imaging and biomarkers to predict prostate cancer progression more accurately.
Whitehead Institute researchers have shown in mouse models that overexpression of the microRNA 125b (miR-125b) can independently cause leukemia and accelerate the disease's progression. Their results are published in this week's online edition of the Proceedings of the National Academy of Sciences (PNAS).
Cellonis Biotechnologies, a Beijing and HK-based medical research and application company, has recorded some remarkable results in the treatment of a twelve-year-old boy with diabetes using their stem cell therapy in a Beijing partner hospital. He has completely regained his normal life, enjoying sports and school activities just like every other person his age, and has been free from injections and drugs for more than half a year.
Novartis today announced a first-of-its-kind collaboration with IBM Watson Health on an initiative to optimize cancer care and improve patient outcomes.
› Verified 8 days ago
NPI Number | 1477251098 |
Organization Name | FALMOUTH OPCO LLC |
Address | 359 Jones Rd, Falmouth, MA 02540 |
Phone Number | 774-349-0220 |
News Archive
Radiation therapy using high-energy particles, like x-rays or electron beams, is a common and critical component in successfully treating patients with brain tumors, but it is also associated with significant adverse effects, such as neuronal loss in adjacent healthy tissues.
Sylvester Comprehensive Cancer Center researchers are looking at ways to combine imaging and biomarkers to predict prostate cancer progression more accurately.
Whitehead Institute researchers have shown in mouse models that overexpression of the microRNA 125b (miR-125b) can independently cause leukemia and accelerate the disease's progression. Their results are published in this week's online edition of the Proceedings of the National Academy of Sciences (PNAS).
Cellonis Biotechnologies, a Beijing and HK-based medical research and application company, has recorded some remarkable results in the treatment of a twelve-year-old boy with diabetes using their stem cell therapy in a Beijing partner hospital. He has completely regained his normal life, enjoying sports and school activities just like every other person his age, and has been free from injections and drugs for more than half a year.
Novartis today announced a first-of-its-kind collaboration with IBM Watson Health on an initiative to optimize cancer care and improve patient outcomes.
› Verified 8 days ago
NPI Number | 1780090266 |
Organization Name | 359 MORSE POND LLC |
Address | 359 Jones Rd, Falmouth, MA 02540 |
Phone Number | 508-457-9000 |
News Archive
Radiation therapy using high-energy particles, like x-rays or electron beams, is a common and critical component in successfully treating patients with brain tumors, but it is also associated with significant adverse effects, such as neuronal loss in adjacent healthy tissues.
Sylvester Comprehensive Cancer Center researchers are looking at ways to combine imaging and biomarkers to predict prostate cancer progression more accurately.
Whitehead Institute researchers have shown in mouse models that overexpression of the microRNA 125b (miR-125b) can independently cause leukemia and accelerate the disease's progression. Their results are published in this week's online edition of the Proceedings of the National Academy of Sciences (PNAS).
Cellonis Biotechnologies, a Beijing and HK-based medical research and application company, has recorded some remarkable results in the treatment of a twelve-year-old boy with diabetes using their stem cell therapy in a Beijing partner hospital. He has completely regained his normal life, enjoying sports and school activities just like every other person his age, and has been free from injections and drugs for more than half a year.
Novartis today announced a first-of-its-kind collaboration with IBM Watson Health on an initiative to optimize cancer care and improve patient outcomes.
› Verified 8 days ago
Ratings from Surveys (Inspections): | |
Ratings from Quality Measures: | |
Ratings from Staffing Data: | |
Overall Rating: |
---|
News Archive
Radiation therapy using high-energy particles, like x-rays or electron beams, is a common and critical component in successfully treating patients with brain tumors, but it is also associated with significant adverse effects, such as neuronal loss in adjacent healthy tissues.
Sylvester Comprehensive Cancer Center researchers are looking at ways to combine imaging and biomarkers to predict prostate cancer progression more accurately.
Whitehead Institute researchers have shown in mouse models that overexpression of the microRNA 125b (miR-125b) can independently cause leukemia and accelerate the disease's progression. Their results are published in this week's online edition of the Proceedings of the National Academy of Sciences (PNAS).
Cellonis Biotechnologies, a Beijing and HK-based medical research and application company, has recorded some remarkable results in the treatment of a twelve-year-old boy with diabetes using their stem cell therapy in a Beijing partner hospital. He has completely regained his normal life, enjoying sports and school activities just like every other person his age, and has been free from injections and drugs for more than half a year.
Novartis today announced a first-of-its-kind collaboration with IBM Watson Health on an initiative to optimize cancer care and improve patient outcomes.
› Verified 8 days ago
Number of Facility Reported Incidents | 0 |
Number of Substantiated Complaints | 0 |
Number of Fines | 0 |
Total Amount of Fines in Dollars | $0 |
Number of Payment Denials | 0 |
Total Number of Penalties | 0 |
Experience Measure | Provider | National Avg. |
---|---|---|
Percentage of long-stay residents whose need for help with daily activities has increased | 17.88 | 14.46 |
Percentage of long-stay residents who lose too much weight | 1.67 | 5.51 |
Percentage of low risk long-stay residents who lose control of their bowels or bladder | 44.64 | 48.41 |
Percentage of long-stay residents with a catheter inserted and left in their bladder | 0.61 | 1.79 |
Percentage of long-stay residents with a urinary tract infection | 1.2 | 2.65 |
Percentage of long-stay residents who have depressive symptoms | 0 | 5.05 |
Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
Percentage of long-stay residents experiencing one or more falls with major injury | 3.68 | 3.36 |
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 95.22 | 93.87 |
Percentage of long-stay residents who received an antipsychotic medication | 24.3 | 14.2 |
Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 75.17 | 83.88 |
Percentage of short-stay residents who newly received an antipsychotic medication | 2.78 | 1.79 |
Percentage of long-stay residents whose ability to move independently worsened | 33.09 | 17.09 |
Percentage of long-stay residents who received an antianxiety or hypnotic medication | 9.95 | 19.7 |
Percentage of high risk long-stay residents with pressure ulcers | 11.46 | 7.32 |
Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 97.32 | 95.98 |
Percentage of short-stay residents who made improvements in function | 65.02 | 67.99 |
Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 82.57 | 82.93 |
News Archive
Radiation therapy using high-energy particles, like x-rays or electron beams, is a common and critical component in successfully treating patients with brain tumors, but it is also associated with significant adverse effects, such as neuronal loss in adjacent healthy tissues.
Sylvester Comprehensive Cancer Center researchers are looking at ways to combine imaging and biomarkers to predict prostate cancer progression more accurately.
Whitehead Institute researchers have shown in mouse models that overexpression of the microRNA 125b (miR-125b) can independently cause leukemia and accelerate the disease's progression. Their results are published in this week's online edition of the Proceedings of the National Academy of Sciences (PNAS).
Cellonis Biotechnologies, a Beijing and HK-based medical research and application company, has recorded some remarkable results in the treatment of a twelve-year-old boy with diabetes using their stem cell therapy in a Beijing partner hospital. He has completely regained his normal life, enjoying sports and school activities just like every other person his age, and has been free from injections and drugs for more than half a year.
Novartis today announced a first-of-its-kind collaboration with IBM Watson Health on an initiative to optimize cancer care and improve patient outcomes.
› Verified 8 days ago